Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis

Nicolaus Kröger, Toni Giorgino, Bart L. Scott, Markus Ditschkowski, Haefaa Alchalby, Francisco Cervantes, Alessandro Vannucchi, Mario Cazzola, Enrica Morra, Tatjana Zabelina, Margherita Maffioli, Arturo Pereira, Dietrich Beelen, H. Joachim Deeg, Francesco Passamonti

Research output: Contribution to journalArticle

Abstract

Allogeneic hematopoietic stem cell transplantation (SCT) is the only curative option for patients with primary myelofibrosis (PMF), but information on its net advantage over conventional therapies is lacking. Using ad hoc statistical analysis, we determined outcomes in 438 patients

Original languageEnglish
Pages (from-to)3347-3350
Number of pages4
JournalBlood
Volume125
Issue number21
DOIs
Publication statusPublished - May 21 2015

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Fingerprint Dive into the research topics of 'Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis'. Together they form a unique fingerprint.

  • Cite this

    Kröger, N., Giorgino, T., Scott, B. L., Ditschkowski, M., Alchalby, H., Cervantes, F., Vannucchi, A., Cazzola, M., Morra, E., Zabelina, T., Maffioli, M., Pereira, A., Beelen, D., Deeg, H. J., & Passamonti, F. (2015). Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood, 125(21), 3347-3350. https://doi.org/10.1182/blood-2014-10-608315